Evolent Health (NYSE:EVH) Stock Gets Price Target Increase from Needham & Company LLC

Evolent Health (NYSE:EVH) had its price objective hoisted by research analysts at Needham & Company LLC from $5.00 to $6.00 in a note issued to investors on Thursday, Benzinga reports. The firm currently has a “buy” rating on the technology company’s stock. Needham & Company LLC‘s price target points to a potential upside of 30.29% from the stock’s previous close.

EVH has been the topic of several other research reports. Citigroup raised Evolent Health from a “neutral” rating to a “buy” rating and cut their price objective for the company from $6.75 to $6.00 in a report on Monday, August 10th. Truist Financial lowered their target price on Evolent Health from $7.00 to $6.00 and set a “hold” rating for the company in a report on Wednesday, August 12th. TD Cowen increased their target price on Evolent Health from $5.00 to $6.00 and gave the company a “buy” rating in a research report on Monday, August 17th. Weiss Ratings lowered Evolent Health from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, October 16th. Finally, Canaccord Genuity Group cut their price target on Evolent Health from $7.00 to $6.00 and set a “buy” rating on the stock in a research note on Monday, August 10th. Eleven equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $6.11.

Evolent Health Price Performance

Shares of Evolent Health stock traded up $0.07 during midday trading on Thursday, hitting $4.61. 1,743,939 shares of the company traded hands, compared to its average volume of 1,816,949. The firm’s fifty day moving average price is $4.17 and its 200-day moving average price is $3.88. The stock has a market cap of $520.64 million, a price-to-earnings ratio of -1.01 and a beta of 1.03. Evolent Health has a 12 month low of $2.10 and a 12 month high of $6.28. The company has a debt-to-equity ratio of 2.52, a quick ratio of 1.24 and a current ratio of 1.24.

Evolent Health (NYSE:EVH) last issued its quarterly earnings data on Thursday, November 5th. The technology company reported $0.06 EPS for the quarter, meeting the consensus estimate of $0.06. The business had revenue of $725.37 million during the quarter, compared to the consensus estimate of $727.06 million. Evolent Health had a negative net margin of 24.08% and a negative return on equity of 4.27%. The firm’s revenue was up 51.3% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.05 EPS. As a group, sell-side analysts forecast that Evolent Health will post -0.25 earnings per share for the current year.

Insider Buying and Selling at Evolent Health

In related news, President Daniel Mccarthy sold 65,892 shares of the stock in a transaction on Wednesday, August 26th. The stock was sold at an average price of $5.00, for a total value of $329,460.00. Following the completion of the sale, the president directly owned 655,133 shares in the company, valued at $3,275,665. This represents a 9.14% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 1.48% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Evolent Health

Institutional investors have recently made changes to their positions in the stock. R Squared Ltd bought a new position in shares of Evolent Health during the first quarter worth about $26,000. Sequoia Financial Advisors LLC acquired a new stake in Evolent Health during the 2nd quarter valued at approximately $78,000. Royal Bank of Canada increased its position in Evolent Health by 51.6% during the 1st quarter. Royal Bank of Canada now owns 25,161 shares of the technology company’s stock valued at $57,000 after purchasing an additional 8,563 shares during the period. WINTON GROUP Ltd increased its position in Evolent Health by 29.6% during the 2nd quarter. WINTON GROUP Ltd now owns 26,700 shares of the technology company’s stock valued at $145,000 after purchasing an additional 6,100 shares during the period. Finally, Wealthfront Advisers LLC raised its holdings in Evolent Health by 40.8% during the 1st quarter. Wealthfront Advisers LLC now owns 28,083 shares of the technology company’s stock worth $64,000 after purchasing an additional 8,136 shares during the last quarter.

Evolent Health News Roundup

Here are the key news stories impacting Evolent Health this week:

• Positive Sentiment: Oppenheimer raised its price target to $7 from $6 and maintained an “outperform” rating, implying substantial upside from the cited $4.61 share price. Oppenheimer recommendations
• Positive Sentiment: Needham & Company lifted its target to $6 from $5 and kept a “buy” rating, adding to the favorable analyst outlook. Needham recommendations
• Positive Sentiment: EVH forecast fiscal 2026 revenue of $2.6 billion to $2.7 billion, with the top of the range above analysts’ $2.6 billion consensus. Third-quarter results and outlook
• Neutral Sentiment: Third-quarter adjusted earnings were $0.06 per share, matching estimates and improving from $0.05 a year earlier. Revenue rose 51.3% year over year to $725.37 million, but was slightly below the $727.06 million consensus. Third-quarter results
• Negative Sentiment: The reported quarter included a negative net margin of 24.08% and negative return on equity, highlighting that profitability remains a concern despite revenue growth and per-share earnings. Third-quarter results

About Evolent Health

Evolent Health, Inc (NYSE: EVH) is a healthcare services and technology company that helps health plans and healthcare providers transition to value-based care. Its platform is designed to support the management of clinical programs, improve patient outcomes and coordinate care while helping customers manage healthcare costs.

The company provides specialty and total-cost-of-care solutions across areas such as cardiology, oncology, musculoskeletal care, radiology and other complex conditions.